BRCA1 and cancer: Efficacy and safety of olaparib and durvalumab combination in patients with solid tumors were then assessed in the MEDIOLA phase 1/2 basket clinical trial (NCT02734004), in 32 patients with different types of cancer characterized by the same BRCA1/2 mutation [283].